

KNOWLEDGE . RESOURCES . TRAINING

New Waived Tests

MLN Matters Number: MM12204 Related Change Request (CR) Number: 12204

Related CR Release Date: April 27, 2021 Effective Date: July 1, 2021

Related CR Transmittal Number: R10721CP Implementation Date: July 6, 2021

PROVIDER TYPES AFFECTED

This MLN Matters Article is for clinical diagnostic laboratories submitting claims to Medicare Administrative Contractors (MACs) for services they provide to Medicare patients

PROVIDER ACTION NEEDED

This article tells you of new Clinical Laboratory Improvement Amendments of 1988 (CLIA) waived tests the FDA has approved. Since these tests are marketed upon approval, CMS must tell the MACs of the new tests so that they can accurately process claims. Make sure your billing staffs are aware of these tests.

BACKGROUND

The CLIA regulations require a facility to be appropriately certified for each test it performs. To make sure Medicare & Medicaid only pay for laboratory tests categorized as waived complexity under CLIA in facilities with a CLIA certificate of waiver, we edit laboratory claims at the CLIA certificate level.

The CPT codes for the new tests we list below must have the modifier QW to be recognized as a waived test. However, the tests mentioned on the first page of the list attached to CR 12204 (for example, CPT codes: 81002, 81025, 82270, 82272, 82962, 83026, 84830, 85013, and 85651) don't require a QW modifier to be recognized as a waived test.

The CPT code, effective date, and description for the latest tests FDA-approved waived tests under CLIA are:

- 80305QW, August 25, 2020, Verify Diagnostics Inc. VeriCheck Drug Test Cup
- 80305QW, August 25, 2020, Verify Diagnostics Inc. VeriCheck Drug Test Dip
- 80305QW, September 23, 2020, Axium BioResearchInc.DrugExam Multi Drug Screen Test
- 80305QW, October 9, 2020, American Screening LLC Discover Panel Dip Card Tests MOR 300





MLN Matters: MM12204 Related CR 12204

 80305QW, October 9, 2020, American Screening LLC Discover Quick Cup Tests MOR 300

- 80305QW, October 9, 2020, American Screening LLC Discover Quick Cup Tests MOR 2000
- 80305QW, October 9, 2020, American Screening LLC Discover Plus Panel Dip Card Tests MOR 300
- 80305QW, October 9, 2020, American Screening LLC Discover Plus Panel Dip Card Tests MOR 2000
- 80305QW, October 9, 2020, American Screening LLC Discover Plus Quick Cup Tests MOR 300
- 80305QW, October 9, 2020, American Screening LLC Discover Plus Quick Cup Tests MOR 2000
- 80305QW, October 9, 2020, American Screening LLC OneScreen Plus Quick Cup Tests MOR300
- 80305QW, October 9, 2020, American Screening LLC OneScreen Plus Quick Cup Tests MOR2000
- 80305QW, October 9, 2020, American Screening LLC Reveal Panel Dip Card Tests MOR2000
- 80305QW, October 9, 2020, American Screening LLC Reveal Quick Cup Tests MOR300
- 80305QW, October 9, 2020, American Screening LLC Reveal Quick Cup Tests MOR2000

Also, CR 12204 gives the following HSPCS code description changes, effective October 6, 2020:

- HCPCS code 87400 description changed to "Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; Influenza, A or B, each". HCPCS code 87400QW describes the waived testing performed by the Quidel Sofia 2 (Sofia Influenza A+B FIA) and the BD Veritor System for Rapid Detection of Flu A+B (For use with nasal and nasopharyngeal swabs) {Includes a Reader}.
- HCPCS code 87420 description changed to "Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; respiratory syncytial virus". HCPCS code 87420QW describes the waived testing performed by the Quidel Sofia 2 (Sofia RSV FIA) and by the BD Veritor System for Rapid Detection of RSV (For use with nasopharyngeal specimens) {Includes a reader}.
- HCPCS code 87430 changed to "Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; Streptococcus, group A". HCPCS code 87430QW describes the waived





MLN Matters: MM12204 Related CR 12204

testing performed by the Quidel Sofia 2 (Sofia Strep A+ FIA) (from throat swab only) and the BD Veritor System for Rapid Detection of Group A Strep (direct from throat swab).

ADDITIONAL INFORMATION

Note: MACs won't search their files to adjust payment for impacted claims they processed before implementing CR 12204. However, they will adjust such claims that you bring to their attention.

We issued CR 12204 to your MAC as the official instruction for this change.

For more information, contact your MAC.

DOCUMENT HISTORY

Date of Change		Description	
April 27, 2021	Initial article released.		

Disclaimer: Paid for by the Department of Health & Human Services. This article was prepared as a service to the public and is not intended to grant rights or impose obligations. This article may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the written law or regulations. We encourage readers to review the specific statutes, regulations and other interpretive materials for a full and accurate statement of their contents. CPT only copyright 2020 American Medical Association. All rights reserved.

Copyright © 2013-2021, the American Hospital Association, Chicago, Illinois. Reproduced by CMS with permission. No portion of the AHA copyrighted materials contained within this publication may be copied without the express written consent of the AHA. AHA copyrighted materials including the UB-04 codes and descriptions may not be removed, copied, or utilized within any software, product, service, solution or derivative work without the written consent of the AHA. If an entity wishes to utilize any AHA materials, please contact the AHA at 312-893-6816. Making copies or utilizing the content of the UB-04 Manual, including the codes and/or descriptions, for internal purposes, resale and/or to be used in any product or publication; creating any modified or derivative work of the UB-04 Manual and/or codes and descriptions; and/or making any commercial use of UB-04 Manual or any portion thereof, including the codes and/or descriptions, is only authorized with an express license from the American Hospital Association. To license the electronic data file of UB-04 Data Specifications, contact Tim Carlson at (312) 893-6816. You may also contact us at ub04@healthforum.com

The American Hospital Association (the "AHA") has not reviewed, and is not responsible for, the completeness or accuracy of any information contained in this material, nor was the AHA or any of its affiliates, involved in the preparation of this material, or the analysis of information provided in the material. The views and/or positions presented in the material do not necessarily represent the views of the AHA. CMS and its products and services are not endorsed by the AHA or any of its affiliates.



